Business Description
Opus Genetics is a clinical-stage company focused on developing treatments for inherited and other serious eye diseases, with a particular emphasis on gene therapies that aim to restore or preserve vision. Its pipeline includes several programs targeting rare genetic conditions that cause blindness, ranging from early clinical trials to earlier-stage research, as well as drug treatments for conditions such as diabetic retinopathy and age-related vision changes. Founded in 2018 and based in Durham, North Carolina, the company was previously known as Ocuphire Pharma before adopting its current name in November 2020.
